Antibody therapy for histoplasmosis

Joshua D. Nosanchuk, Rosely M. Zancopé-Oliveira, Andrew J. Hamilton, Allan J. Guimarães

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


The endemic human pathogenicfungusHistoplasmacapsulatum isamajor fungal pathogen with a broad variety of clinical presentations, ranging from mild, focal pulmonary disease to life-threatening systemic infections. Although azoles, such as itraconazole and voriconazole, and amphotericin B have significant activity against H. capsulatum, about 1 in 10 patients hospitalized due to histoplasmosis die. Hence, new approaches for managing disease are being sought. Over the past 10years, studies have demonstrated that monoclonal antibodies (mAbs) can modify the pathogenesis of histoplasmosis. Disease has been shown to be impacted by mAbs targeting either fungal cell surface proteins or host co-stimulatory molecules. This review will detail our current knowledge regarding the impact of antibody therapy on histoplasmosis.

Original languageEnglish (US)
JournalFrontiers in Microbiology
Issue numberFEB
StatePublished - 2012


  • Antibody
  • Co-stimulation
  • Heat shock protein 60
  • Histone 2B
  • Histoplasma capsulatum
  • Histoplasmosis
  • M antigen

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)


Dive into the research topics of 'Antibody therapy for histoplasmosis'. Together they form a unique fingerprint.

Cite this